Atossa Therapeutics, INC 8-K filings

Atossa Therapeutics reported Q2 2026 results, detailing progress in rare disease and oncology drug development for (Z)-endoxifen, alongside a capital raise.

Atossa Therapeutics announced a registered direct offering of common stock and warrants, aiming to raise approximately $4.1 million for clinical development and general corporate purposes.

Atossa Therapeutics reported Q1 2026 financial results, highlighting progress in (Z)-endoxifen development for oncology and rare diseases, including FDA designations for DMD and McCune-Albright Syndrome.

Atossa Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where directors were elected, the independent auditor was ratified, and an amendment for a potential reverse stock split was approved.

Atossa Therapeutics has entered into a settlement agreement with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve ongoing patent disputes regarding its Endoxifen intellectual property.

Atossa Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a strategic pivot towards rare disease indications for its lead drug candidate, (Z)-endoxifen, alongside ongoing breast cancer programs.

Atossa Therapeutics issued its 2026 Letter to Shareholders, detailing 2025 accomplishments in oncology and rare diseases, and outlining strategic priorities for 2026.

Atossa Therapeutics, Inc. will implement a 1-for-15 reverse stock split effective February 2, 2026, to maintain Nasdaq listing compliance.

Atossa Therapeutics announced an estimated $40 million in cash and cash equivalents as of December 31, 2025, supporting its advanced (Z)-Endoxifen clinical pipeline for breast cancer and new indications.

Atossa Therapeutics announced the FDA issued a 'Study May Proceed' letter for its investigational new drug application of (Z)-Endoxifen for metastatic breast cancer.

Atossa Therapeutics announced the completion of a Type C meeting with the FDA, clarifying expedited regulatory pathways for (Z)-endoxifen across multiple breast cancer indications.

Atossa Therapeutics reports increased Q3 2025 operating expenses and net loss, while advancing its (Z)-endoxifen clinical programs and engaging with the FDA for accelerated development.

Atossa Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Mark Daniel as its new Chief Financial Officer, effective October 14, 2025, as it prepares for commercial operations.

Atossa Therapeutics, Inc. provided a corporate presentation detailing the clinical progress, market opportunity, and financial position of its lead drug candidate, (Z)-endoxifen, for breast cancer.

Atossa Therapeutics seeks FDA meeting to fast-track low-dose (Z)-endoxifen for breast cancer risk reduction.

Atossa Therapeutics, Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to February 17, 2026.

Atossa Therapeutics reports positive FDA feedback and strong Phase 2 clinical results for its lead breast cancer drug, (Z)-endoxifen, paving the way for a Q4 2025 IND submission.

Atossa Therapeutics reports Q1 2025 financial results, highlights strategic focus on metastatic breast cancer, and strengthens its (Z)-endoxifen patent portfolio.

Atossa Therapeutics held its 2025 Annual Meeting of Stockholders on May 8, 2025, with all director nominees elected and proposals approved.

Atossa Therapeutics is contesting Post Grant Review (PGR) and Inter Partes Review (IPR) petitions filed by Intas Pharmaceuticals against two of its patents related to Endoxifen.

Atossa Therapeutics reported its full year 2024 financial results, highlighting a strategic shift to focus on metastatic breast cancer and ending the year with $71.1 million in cash and cash equivalents.

Atossa Therapeutics shifts focus to metastatic breast cancer for (Z)-endoxifen, aiming for faster regulatory approval while pursuing additional indications with the FDA.

Atossa Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Atossa Therapeutics announces a response to an unfavorable PTAB ruling regarding U.S. Patent No. 11,572,334, while also highlighting the issuance of a new patent, U.S. Patent No. 12,201,591, related to sustained release compositions of endoxifen.

Atossa Therapeutics announced the presentation of pharmacokinetic and tolerability data from their Phase 2 EVANGELINE trial of (Z)-endoxifen at the San Antonio Breast Cancer Symposium, showing promising results for premenopausal women with ER+/HER2breast cancer.

Atossa Therapeutics has entered into an agreement to sell up to $100 million of its common stock through an at-the-market offering.

Atossa Therapeutics reported positive results from a Phase 2 study of (Z)-endoxifen, showing significant reductions in mammographic breast density, and provided a corporate update including financial results for the third quarter of 2024.

Atossa Therapeutics reports positive topline data from its Phase 2 KARISMA-Endoxifen study, showing significant reduction in mammographic breast density in premenopausal women.

Atossa Therapeutics announced its second quarter 2024 financial results, showcasing clinical advancements and a solid cash balance of $79.5 million.

Atossa Therapeutics' annual meeting saw stockholders approve an increase in authorized shares and an amendment to the 2020 Stock Incentive Plan, while the company appointed a new Chief Financial Officer.